Comparative Pharmacology
Head-to-head clinical analysis: IMODIUM A D versus LOMANATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMODIUM A D versus LOMANATE.
IMODIUM A-D vs LOMANATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide is a synthetic piperidine derivative that acts as an agonist at mu-opioid receptors in the myenteric plexus of the gastrointestinal tract. It inhibits peristalsis by decreasing circular and longitudinal smooth muscle activity, prolonging gastrointestinal transit time, and increasing water and electrolyte absorption. It also increases anal sphincter tone, reducing fecal urgency and incontinence. Loperamide has poor bioavailability and does not cross the blood-brain barrier significantly at therapeutic doses, limiting central opioid effects.
LOMANATE is a combination of diphenoxylate (a peripheral opioid receptor agonist that slows GI motility) and atropine (an anticholinergic that discourages abuse).
4 mg orally initially, then 2 mg after each unformed stool; maximum 8 mg/day for OTC use; 16 mg/day for prescription use. Duration not to exceed 2 days.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 9-14 hours (mean 11.2 hours) in patients with diarrhea; clinical significance: steady-state achieved within 2-4 days.
Terminal elimination half-life is 18-24 hours in adults with normal renal function; prolonged to 40-60 hours in severe renal impairment (CrCl < 30 mL/min), requiring dose adjustment.
Primarily fecal (approximately 95% as unchanged drug and metabolites) with minimal renal excretion (<1% unchanged).
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal (15%); 5% eliminated via other routes.
Category C
Category C
Antidiarrheal
Antidiarrheal